Wyatt Technolgy uDAWN MALS, UTrEX, and QELS systems

Added: Aug 09, 2017 2:32 pm This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Wyatt Technology, Santa Barbara, CA to procure a uDAWN MALS, Optilab UTrEX and WyattQELS Systems.

The Wyatt Technology Systems will be used in support of ongoing research at the Laboratory of Malaria Immunology and Vaccinology (LMIV) to research, pursue, produce and clinical trial malaria vaccines. Place of Performance is Rockville, MD 20852.

The LMIV develops and performs clinical evaluation of prototype malaria vaccines. The Wyatt detection machines are needed for each vaccine that has to undergo a rigorous development process. This includes creation of expression systems, fermentation optimization, scale-up of purification technology, clinical good manufacturing practices (cGMP) production, formulation, quality control, preclinical testing, and clinical trials. Only the systems listed meet the needs based on the narrow peaks produced by UHPLC-SEC in the LMIV.

The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-RML-D-1861853) to Skye Duffner at skye.duffner@nih.gov by 5:00 pm eastern standard time Monday, August 23, 2017. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.